Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Lithium for Suicidal Behavior in Mood Disorders
NCT01928446 · VA Office of Research and Development · PHASE2/PHASE3 · terminated · last registry update 2024-04-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “terminated early due to non-safety related DMC recommendations” | – | Registry record, VA Office of Research and Development |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IMPA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-16Phase 3 first posted: Bristol-Myers Squibb, KarXT + Lithium (NCT06929273)
- 2025-03-25Also stopped (terminated): University Hospital, Montpellier, Blood sample (NCT04461327)
- 2025-03-24Results posted on the registry: Solventum US LLC, a drug against IMPA1 (NCT04279574)
- 2025-03-05Results posted on the registry: State University of New York at Buffalo, Lithium + Placebo (NCT05618587)
- 2025-02-03Results posted on the registry: Columbia University, Lithium Carbonate + Placebo (NCT02862210)
- 2025-01-23Phase 3 first posted: University of Milan, Lithium Carbonate Capsule (NCT06789783)
- 2024-10-17Results posted on the registry: University of California, Irvine, sertraline, lithium (NCT00581009)
- 2024-09-19Also stopped (withdrawn): Nova Scotia Health Authority, Lithium + Paroxetine (NCT01416220)
- 2024-07-25Also stopped (terminated): University of Michigan, a drug against IMPA1 (NCT03036566)
- 2023-08-23Phase 3 first posted: Stichting TRICALS Foundation, Lithium Carbonate 400 MG (NCT06008249)
- 2023-08-03Phase 3 first posted: Dr. Inge Winter, Escitalopram + Sertraline (NCT05973786)
- 2023-05-17Results posted on the registry: Intra-Cellular Therapies, Inc., Lumateperone (ITI-007) + Placebo (NCT02600507)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision